Showing 7661-7670 of 8546 results for "".
- Galderma Launches Online Epiduo Adherence Programhttps://practicaldermatology.com/news/20130312-galderma_launches_online_epiduo_adherence_program/2459593/Galderma announced its new Epiduo TAP (Treatment, Adherence, and Performance) Program, an online and mobile patient platform that educates acne patients ages 13 and older about the proper application of Epiduo (adapalene and benzoyl peroxide 0.1%/2.5%) Gel and encourages acne patients to stay adhere
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- AAD Unveils New App for Diagnosing and Treating Psoriasishttps://practicaldermatology.com/news/20130311-aad_unveils_new_app_for_diagnosing_and_treating_psoriasis/2459599/At its recent annual meeting in Miami, The American Academy of Dermatology introduced a mobile app of evidence-based clinical guidelines for diagnosing and treating psoriasis and psoriatic arthritis. The free app includes a clinical decision tree; reference guide for diagnoses; arthritic diagnostic
- Valeant Launches Acne Scholarship Programhttps://practicaldermatology.com/news/20130311-valeant_launches_acne_scholarship_program/2459598/Valeant Dermatology recently launched a scholarship program entitled, Acanya® I Can Succeed, an initiative that will provide college scholarship money to students who have had acne and have actively tried to address it. The Acanya I Can Succeed Scholarship program will award a total of up to $48,000
- PreCision Dermatology Appoints Chief Operating Officerhttps://practicaldermatology.com/news/20130307-precision_dermatology_appoints_chief_operating_officer/2459601/Robert Moccia has been appointed to the newly created position of Chief Operating Officer of PreCision Dermatology, Inc. In that role, all operating functions of PreCision will report to Mr. Moccia. In addition, Mr Moccia will serve as the President of Onset Dermatologics, LLC, a wholly owned subsid
- Novan Therapeutics Presents Data for Potential Topical Agent that Reduces Sebum in Acne Patientshttps://practicaldermatology.com/news/20130228-novan_therapeutics_presents_data_for_potential_topical_agent_that_reduces_sebum_in_acne_patients/2459602/Recent in vitro and animal testing data from Novan Therapeutics indicate that the company's drug candidate, SB204, could lead to a topical treatment for acne that reduces oil production in the skin. Dr. Diane Thiboutot, Professor of Dermatology at Penn State Hershey College of Medicine, notes that,
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Brickell Biotech Announces Funding for Development of Novel Dermatology Treatmentshttps://practicaldermatology.com/news/20130226-brickell_biotech_announces_funding_for_development_of_novel_dermatology_treatments/2459608/Brickell Biotech, Inc., a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, announced a $7 million Series B financing round to fund new chemical entities in dermatology for indications including acne, atopic dermatiti
- CeraVe Launches Seven New Sunscreens with Barrier-Repairing Ceramideshttps://practicaldermatology.com/news/20130225-cerave_launches_seven_new_sunscreens_with_barrier-repairing_ceramides/2459609/Seven newCeraVe sunscreening products are now available in the Sun Protection aisle at drugstores and mass market retailers nationwide. The CeraVe Sun Care line, developed with dermatologists, includes products for the face and body with various applications offe